Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17752829 | 0.92 | IDO1 (0.52) | IDO1TP53TAAR1CYP2A6LPL | |
| SCHEMBL17752820 | 0.92 | IDO1 (0.52) | IDO1TP53TAAR1CYP2A6LPL | |
| SCHEMBL17752815 | 0.92 | IDO1 (0.52) | IDO1TP53TAAR1CYP2A6LPL | |
| SCHEMBL127369 | 0.83 | IDO1 (0.69) | IDO1ALDH1A1TSHRTDP1 | |
| SCHEMBL36295 | 0.83 | TP53 (0.67) | IDO1TP53TAAR1CYP2A6LPL | |
| SCHEMBL17752822 | 0.82 | TP53 (0.47) | IDO1TP53ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL31498555 | 0.79 | TP53 (0.62) | IDO1TP53TAAR1CYP2A6LPL | |
| Ammonia Solution, Strong SCHEMBL27293386 | 0.79 | TP53 (0.62) | IDO1TP53TAAR1CYP2A6LPL | |
| SCHEMBL7542835 | 0.79 | TP53 (0.62) | IDO1TP53TAAR1CYP2A6LPL | |
| SCHEMBL28166306 | 0.79 | TP53 (0.62) | IDO1TP53TAAR1CYP2A6LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5162556-A | Used for forming a thin metal gold layer or film on a substrate | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-10 | — | — | US | claimed |
| US-20240018302-A1 | BIORESORBABLE, STEREOCHEMICALLY DEFINED ELASTOMERS AND METHODS OF MAKING AND USING SAME | UNIV DUKE (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230383056-A1 | BIORESORBABLE,STEREOCHEMICALLY DEFINED ELASTOMERS AND METHODS OF MAKING AND USING SAME | DUKE UNIVERSITY (US) | 2023-11-30 | — | — | US | disclosed |
| US-11685809-B2 | Phosphorus-containing polymers, and methods of producing thereof | NOVOMER, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210024489-A1 | TREATMENT AND PREVENTION OF NEUROPATHIC PAIN WITH P2Y14 ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-28 | — | — | US | disclosed |
| US-9975971-B2 | Preparation of polyisobutylene-based polymer networks by thiol-ene chemistry | THE UNIVERSITY OF AKRON (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2017184735-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20160002373-A1 | PREPARATION OF POLYISOBUTYLENE-BASED POLYMER NETWORKS BY THIOL-ENE CHEMISTRY | THE UNIVERSITY OF AKRON (US) | 2016-01-07 | — | — | US | disclosed |
| CN-1314420-A | Olefine polymerization catalyst and method for preparing olefine polymer | SUMITOMO CHEMICAL CO (JP) | 2001-09-26 | — | — | CN | disclosed |
| EP-1134234-A1 | Olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-1081167-A1 | Olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-07 | — | — | EP | disclosed |
| CN-1286271-A | Olefine polymerization catalyst and method for production of olefine polymer using it | SUMITOMO CHEMICAL CO (JP) | 2001-03-07 | — | — | CN | disclosed |
| CN-1030768-C | Primidine derivatives, process for preparing same and inhibitor for androgen | OTSUKA PHARMA CO LTD (JP) | 1996-01-24 | — | — | CN | disclosed |
| US-5162556-A | Used for forming a thin metal gold layer or film on a substrate | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| CN-1060844-A | Pyrimidine derivatives, its method for making and inhibitor for androgen | OTSUKA PHARMA CO LTD (JP) | 1992-05-06 | — | — | CN | disclosed |
| EP-0314042-A2 | Novel copolymers and superoxide dismutase modified with said copolymers | KURARAY CO., LTD. (JP) | 1989-05-03 | — | — | EP | disclosed |
| EP-0044711-B1 | 9,11-METHANO-13-AZA-11A-CARBATHROMBANOIC ACID ANALOGUES AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-03-14 | — | — | EP | disclosed |
| US-4055574-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, MUSCLE RELAXANT | SYNTEX (U.S.A.) INC. (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | P2RY14, P2RY1, P2RY13 | IDO1 2869/4885TP53 4124/4885TAAR1 405/4885 |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY13 | IDO1 2869/4885TP53 4124/4885TAAR1 405/4885 |
| US-20210024489-A1 | TREATMENT AND PREVENTION OF NEUROPATHIC PAIN WITH P2Y14 ANTAGONISTS | P2RY14, P2RY4, P2RY13 | IDO1 3238/4885TP53 4792/4885TAAR1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.